UPCC 02614: The BAMM Trial: BRAF Autophagy and MEK inhibition in Metastatic Melanoma: A Phase I/II Open Label Trial of Dabrafenib Trametinib and Hydroxychloroquine in Patients with Advanced BRAF Mutant Melanoma

Study Overview

The main purpose of this study is to determine the maximum tolerated dose (MTD) and preliminary safety of hydroxychloroquine (HCQ) when administered in conjunction with oral dabrafenib and trametinib (D+T) in patients with advanced BRAF mutant melanoma. The study will involve mainly standard of care assessments with additional blood draw for PK/PD, tumor biopsy and occular toxicity monitoring.

  • Study Identifier: 819986

Recruitment Status

Open

Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Volunteer Sign up

Volunteer Sign-up

Participate in medical studies to develop new diagnostic and clinical treatments and improve current standards of care.

Sign Up Now!

If you need assistance finding a non-cancer study or if you have any questions, please email psom-ocr@pobox.upenn.edu